Mantle cell lymphoma · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Lenalidomide and Rituximab (R2) Variant #10 | — | R 86 746 | 35d | — | ~8.5 mo | — | — | 1 |
Bortezomib monotherapy Variant #14 | — | R 8 539 | 35d | ~30.3 mo | — | ~27 | ~R 230 565 PFS proxy · indirect | 5 |
Lenalidomide monotherapy N/A - secondary systemic drug | — | R 6 361 | 90d | — | — | — | — | 1 |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | — | — | — | — | 2 |
Interferon alfa monotherapy Variant #01 Partial | — | — | 7d | — | — | — | — | — |
Observation Partial | — | — | — | — | — | — | — | 1 |
6 of 6 regimens shown